Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Metabolomic Analysis of Exhaled Breath Condensate in Asthmatics

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2011 by National Taiwan University Hospital.
Recruitment status was:  Not yet recruiting
Sponsor:
Information provided by (Responsible Party):
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT01439737
First received: September 21, 2011
Last updated: September 22, 2011
Last verified: September 2011

September 21, 2011
September 22, 2011
September 2011
December 2014   (final data collection date for primary outcome measure)
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Metabolomic Analysis of Exhaled Breath Condensate in Asthmatics
Metabolomic Analysis of Exhaled Breath Condensate, Plasma and Urine Specimens in Adult Asthmatics
Asthma is a chronic inflammatory airway disease. Significant heterogeneity exists in the clinical manifestations and treatment responses in these patients. Metabolomics is a large-scale approach to monitoring as many as possible of the compounds involved in cellular processes in a single assay to derive metabolic profiles. Compared with genomics or proteomics, metabolomics reflects changes in phenotype and therefore function. Up to now, few studies have evaluated the role of metabolomic analysis in the diagnosis and prognostic evaluation of airway disorders. Collection of exhaled breath condensate (EBC) is a newly developed, noninvasive method that may allow clinicians and researchers to assess biochemical profiles in the alveolar lining fluid. This study will apply metabolomics to examine the biomarkers in the EBCs, serum and urine specimens in adult asthmatics.
The aims of this study are: 1. Metabolomic profiling of the exhaled breath condensate (EBC), serum and urine specimens in adult asthmatics; 2. Correlation between metabolomic profiles of these specimens with the severity and control of asthma; 3. Comparing metabolomic profiles in asthmatics with different phenotypes and endotypes; 4.Comparing metabolomic profiles obtained from asthmatics during stable and acute exacerbation periods; 5. Comparing metabolomic profiles in asthmatics before and after inhaled corticosteroid therapy.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
Exhaled breath condensates, serum, urine
Non-Probability Sample
Adult asthmatics
Asthma
Not Provided
asthma
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
300
December 2014
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. 20-90 years
  2. Diagnosis of asthma based on the GINA guideline

Exclusion Criteria:

  1. Patient with cancer
  2. Patient with long-term ventilator use
Both
20 Years to 90 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Taiwan
 
NCT01439737
201108051RC
No
Not Provided
Not Provided
National Taiwan University Hospital
National Taiwan University Hospital
Not Provided
Principal Investigator: Ping-Hung Kuo National Taiwan University Hospital
National Taiwan University Hospital
September 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP